Skip to main content
Clinical Trials/NCT05565534
NCT05565534
Completed
Not Applicable

Optimizing Delivery of Diabetes Management During Breast Cancer Care

Weill Medical College of Cornell University3 sites in 1 country74 target enrollmentFebruary 28, 2023

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Breast Cancer
Sponsor
Weill Medical College of Cornell University
Enrollment
74
Locations
3
Primary Endpoint
Provider Questionnaire: Self-report of intervention feasibility
Status
Completed
Last Updated
4 months ago

Overview

Brief Summary

The goal of this study is to find a new way to make diabetes care better for patients with breast cancer and diabetes who are currently receiving cancer treatment. We will have two groups, the researchers will decide who is in which group. One group will be working with a nurse who is trained in diabetes care while the other does not. This will allow the investigators to see if having a trained nurse as part of the care team can help improve the care the patients receive.

Detailed Description

The present study aims to develop a stakeholder-engaged nurse practitioner (NP)-led intervention to improve diabetes care for patients with breast cancer and diabetes who are undergoing cancer treatment. This is a pilot feasibility study, in which we will use a quasi-experimental pre-post design with non-randomized intervention and control groups. In this feasibility study, the investigators will first enroll 38 eligible patients for the control group and collect effectiveness measures at baseline and follow-up (end of chemotherapy or other cancer treatment, \~12 weeks). Through chart review, the investigators will document cancer treatment regimen completion at follow-up. The investigators will then enroll 38 patients for the intervention group, collecting the effectiveness and implementation outcomes at the end of their treatment (\~12 weeks). The main hypothesis that will be tested in this pilot study is that a nurse practitioner embedded in the oncology team who is trained in diabetes management may successfully manage diabetes during active cancer care for patients undergoing cancer treatment.

Registry
clinicaltrials.gov
Start Date
February 28, 2023
End Date
October 6, 2025
Last Updated
4 months ago
Study Type
Interventional
Study Design
Sequential
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Newly diagnosed invasive cancer
  • Plan to receive neo-adjuvant or adjuvant chemotherapy, targeted therapy, hormonal therapy, or radiation at Weill Cornell Medicine (WCM)
  • Age 18+ years
  • Pre-diabetes OR type 2 diabetes. Treatment with antidiabetic medication OR
  • HbA1c greater than or equal to 5.7 OR
  • Random glucose greater than or equal to OR
  • Fasting blood glucose greater than or equal to 100

Exclusion Criteria

  • Patients receiving hospice care
  • Type 1 diabetes

Outcomes

Primary Outcomes

Provider Questionnaire: Self-report of intervention feasibility

Time Frame: Immediately post-intervention at the week 12 follow-up

Questionnaire: Feasibility of Intervention Measure (4 items) Response Scale: For each item, respondents can choose a value from 1-5. Scales can be created for the measure by averaging responses for all 4 items for the overall score. The average score range is from 1 to 5 with higher scores indicating that the intervention is very feasible, and lower scores (below 3) indicating the intervention is not feasible.

Provider Questionnaire: Self-report of intervention acceptability

Time Frame: Immediately post-intervention at the week 12 follow-up

Questionnaire: Acceptability of Intervention Measure (4 items) Response Scale: For each item, respondents can choose a value from 1-5. Scales can be created for the measure by averaging responses for all 4 items for the overall score. The average score range is from 1 to 5 with higher scores indicating more favorable attitudes toward the intervention and lower scores (below 3) indicating less favorable attitudes.

Intervention Completion Success Ratio

Time Frame: 2 years

Only for the interventional group The number of participants who completed intervention divided by the number of participants who enrolled

Data Collection Success Ratio

Time Frame: 2 years

Number of participants who completed both surveys divided by the number of participants who were enrolled.

Patient Questionnaire: Self-report of intervention acceptability

Time Frame: Immediately post-intervention at the week 12 follow-up

Questionnaire: Acceptability of Intervention Measure (4 items) Response Scale: For each item, respondents can choose a value from 1-5. Scales can be created for the measure by averaging responses for all 4 items for the overall score. The average score range is from 1 to 5 with higher scores indicating more favorable attitudes toward the intervention and lower scores (below 3) indicating less favorable attitudes.

Recruitment Success Ratio

Time Frame: 2 years

Number of participants recruited divided by the number of participants approached

Patient Questionnaire: Self-report of intervention feasibility

Time Frame: Immediately post-intervention at the week 12 follow-up

Questionnaire: Feasibility of Intervention Measure (4 items) Response Scale: For each item, respondents can choose a value from 1-5. Scales can be created for the measure by averaging responses for all 4 items for the overall score. The average score range is from 1 to 5 with higher scores indicating that the intervention is very feasible, and lower scores (below 3) indicating the intervention is not feasible.

Patient Questionnaire: Self-report of intervention appropriateness

Time Frame: Immediately post-intervention at the week 12 follow-up

Questionnaire: Intervention Appropriateness Measure (4 items) Response Scale: For each item, respondents can choose a value from 1-5. Scales can be created for the measure by averaging responses for all 4 items for the overall score. The average score range is from 1 to 5 with higher scores indicating the intervention suits their needs well and lower scores (below 3) indicating the intervention does not fit their needs well.

Provider Questionnaire: Self-report of intervention appropriateness

Time Frame: Immediately post-intervention at the week 12 follow-up

Questionnaire: Intervention Appropriateness Measure (4 items) Response Scale: For each item, respondents can choose a value from 1-5. Scales can be created for the measure by averaging responses for all 4 items for the overall score. The average score range is from 1 to 5 with higher scores indicating the intervention suits their needs well and lower scores (below 3) indicating the intervention does not fit their needs well.

Ratio of patients who receive a summary document at the end of the intervention

Time Frame: 2 years

Number of patients who receive a summary document compared to the number of patients who complete the follow-up visit.

Number of in-person, virtual or phone contacts with the NP

Time Frame: 2 years

This will assess the degree to which the intervention was implemented over the course of the study

Secondary Outcomes

  • Number of missed chemotherapy doses(From baseline to Week 12 follow-up)
  • Change in Patient Self-report Responses of Diabetes Treatment Satisfaction Questionnaire(From baseline to week 12 follow-up visit)
  • Change in Patient Self-report Responses of Neuropathy as Measured By the PRO-CTCAE Survey(From baseline to week 12 follow-up visit)
  • Change in Patient Self-report Responses of Diabetes Distress Scale Questionnaire(From baseline to Week 12 follow-up)
  • Change in Patient Self-report Responses of the Audit of Diabetes Dependent QoL Questionnaire(From baseline to Week 12 follow-up)
  • Change in Patient Self-report Responses of the Functional Assessment of Cancer Therapy-Breast Questionnaire(From baseline to Week 12 follow-up)
  • Change in number of Hospitalizations Since Cancer Diagnosis(From baseline to Week 12 follow-up)
  • Change in number of Emergency Department (ED) Visits Since Cancer Diagnosis(From baseline to Week 12 follow-up)
  • Number of participants with a Delay in Chemotherapy Administration(From baseline to Week 12 follow-up)
  • Number of participants with Chemotherapy Dose Reductions(From baseline to Week 12 follow-up)

Study Sites (3)

Loading locations...

Similar Trials